Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Karyopharm Therapeutics today and set a price target of $12.00. The company’s shares closed yesterday at $5.90.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Tenthoff is an analyst with an average return of -9.8% and a 36.21% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Skye Bioscience, and Alnylam Pharma.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Karyopharm Therapeutics with a $16.60 average price target.
Based on Karyopharm Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $37.93 million and a GAAP net loss of $37.25 million. In comparison, last year the company earned a revenue of $42.79 million and had a net profit of $23.79 million
Read More on KPTI:
Disclaimer & DisclosureReport an Issue
- Karyopharm Therapeutics: Strategic Financing Extends Cash Runway Amid Cautious Hold Rating
- Karyopharm price target lowered to $6 from $8 at Leerink
- Morning Movers: AST SpaceMobile jumps after direct-to-cellular pact with Verizon
- Karyopharm Secures $100M Financing for Clinical Trials
- Karyopharm announces $100M strategic financing plan
/Alphabet%20(Google)%20Image%20by%20Markus%20Mainka%20via%20Shutterstock.jpg)
/Netflix%20on%20tv%20with%20remote%20by%20freestocks%20via%20Unsplash.jpg)
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
